49%CRO/CMO

5%Academic

2% Biotech

14% Small–mid

2% Generic

19% Large

Pharma &Biotech

37%

About our respondents

As part of our Spotlight on future trends in outsourcing, we carried out a survey, which was completed by a number of CRO, Pharma & Biotecth leaders within the industry, on various aspects on outsourcing. The results of the survey can be seen in this infographic.

Future trends in outsourcing

The future of bioanalytical outsourcing

Pharma vs CRO

Criteria

In 2018, companies currentlyoutsourcing more than 60%

of bioanalytical work willincrease by 11%

In 2018, companies currentlyoutsourcing less than 40%of their bioanalytical work

will decrease by 14%

Percentage of work outsourced

Barriers faced, which would prevent Pharma from outsourcing work again?

“Unresponsiveness and imprecise data”

“Regulatory complianceand scientific expertise”

“Staff not understanding regulations or doing workaccording to protocols”

“Timelines that could not be met”

In what ways can CROs and Pharma work together?

Better communication

Shared training/exchangeof staff

Longer on-going relationships

Better understandings ofexpectations before project

Location

Role

North America Chemist/scientist 21%

Director/CEO/VP 19%

Manager/Group leader 48%

Technician 0%Other 11%

42%

Europe 42%

Asia9%

4%Rest of the world

How are CROs coping with the change in sample number?

“Improve efficiency& hire more staff”

“Introduction of automation”

“Constantly changing priorities to meet customer

demand”

“Investment (instrumentation,

automation, staff)”

Has the number of samples recieved by CROsfor analysis changed in the last 2 years?

Decre

ased

9%

Incre

ased

57%

Rem

ained

simila

r

33%

Mid-sizedPharma

91% 85%

Small-sizedPharma

78%

LargePharma

70%Biotechs

36%Academia

6%Other

General

Top three reasons for change in outsourcing:

Is there a rightful demand for Pharma to share all aspects of clinical information ofa particular project to CRO’s?

1) Reductions in in-house capabilities2) Increasing complexity of molecules

3) Time pressures

Yes – completely

16%

No –only information

relating to outsourcedwork 19%

Yes – to some degree

63%

26%

40%

2016

2018

71%

60%

2016

2018

What criteria do CROs think is important to Pharma when

choosing a partner

What critera do Pharma actually think is important when

choosing a CRO

Previously worked with them

50%

50%

65%

Specialized in that area

Cost

Cost

52%

61%

75%

Speed of process

Recommendation/reuptation

2% Culture

4% Equipment

3% Other: history of regulatory compliance, quality & strategic relationship

13% Location

8% Culture

13% Equipment

Most important

Least important

63%Scientific lead

15% Project manager

22%Procurement

Key elements for successful outsourced work

Good quality and meetingtimeline

COMMUNICATION

Successful compliance withregulations

Trust

Who makes the final decision on outsourcing?